Exelixis Clinical Trials
Exelixis is currently enrolling patients in our two cabozantinib phase 3 prostate cancer trials, COMET-1 and COMET-2. We are also continuing to follow patients enrolled in our phase 2 Randomized Discontinuation Trial (RDT), which is evaluating cabozantinib in a variety of cancer indications, and in a phase 1B study that is evaluating potential interactions between cabozantinib and other drugs in patients with renal cell carcinoma or differentiated thyroid cancer.
|Status||Tumor Types Covered||Trial Description||Phase||Trial Information1|
|Active, enrollment completed||Castration-Resistant Prostate Cancer||Efficacy of cabozantinib (XL184) versus prednisone in castration-resistant prostate cancer (COMET-1):
evaluation of overall survival.
|Recruiting||Castration-Resistant Prostate Cancer||Efficacy of cabozantinib (XL184) versus mitoxantrone plus prednisone in castration-resistant prostate cancer (COMET-2): evaluation of pain response.||Phase 3||NCT01522443|
|Recruiting||Metastatic Renal Cell Carcinoma||A Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma (METEOR).||Phase 3||NCT01865747|
|Recruiting||Hepatocellular Carcinoma||A Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL)||Phase 3||NCT01908426|
|Approved for marketing||Medullary Thyroid Cancer||Expanded Access Study of Cabozantinib (XL184) in Medullary Thyroid Cancer||Expanded Access||NCT01683110|
|Not yet recruiting||Medullary Thyroid Cancer||A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer||Phase 4||NCT01896479|
|Active, enrollment completed||Medullary Thyroid Cancer||Efficacy of cabozantinib (XL184) in Advanced Medullary Thyroid Cancer (EXAM)||Phase 3||NCT00704730|
|Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer||Phase 1||NCT01553656|
|Recruiting||Healthy Hepatic Impairment||Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects||Phase 1||NCT01493869|
|Recruiting||Healthy Renal Impairment||A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function||Phase 1||NCT01761773|
|Active, enrollment completed||Breast Cancer
Gastric/GE Junctional Cancer
Castration-Resistant Prostate Cancer
Non-small Cell Lung Cancer
Small Cell Lung Cancer
|Randomized Discontinuation Trial (RDT)
Study of cabozantinib in Adults With Advanced Malignancies
|Active, enrollment completed||Glioblastoma Multiforme||Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme||Phase 2||NCT00704288|
|Active, enrollment completed||Astrocytic Tumors||Study of Multiple Doses and Regimens of XL184 (Cabozantinib) in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse||Phase 2||NCT01068782|
|Active, enrollment completed||Glioblastoma
Giant Cell Glioblastoma
|Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma||Phase 1||NCT00960492|
For more information on the Phase 3 COMET clinical trials in Castration Resistant Prostate Cancer please visit CometClinicalTrials.com.
For a detailed list of cabozantinib clinical studies posted on ClinicalTrials.gov please click HERE. For further information regarding all clinical trials please contact Exelixis Medical Information at 1-888-EXELIXIS (1-888-393-5494) or at email@example.com.
- U.S. National Institutes of Health, ClinicalTrials.gov Web site: http://www.clinicaltrials.gov/